{"id":"NCT03643965","sponsor":"Calliditas Therapeutics AB","briefTitle":"Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy","officialTitle":"A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-05","primaryCompletion":"2023-07-10","completion":"2023-07-10","firstPosted":"2018-08-23","resultsPosted":"2024-12-03","lastUpdate":"2024-12-03"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary IgA Nephropathy"],"interventions":[{"type":"DRUG","name":"Nefecon","otherNames":["Budesonide modified released capsule"]},{"type":"DRUG","name":"Placebo oral capsule","otherNames":["Placebo"]}],"arms":[{"label":"Nefecon","type":"EXPERIMENTAL"},{"label":"Placebo oral capsule","type":"PLACEBO_COMPARATOR"}],"summary":"The overall aim of the study is to evaluate the efficacy, safety, and tolerability of Nefecon 16 mg per day in the treatment of patients with primary IgAN (Immunoglobulin A nephropathy) at risk of progressing to end-stage renal disease (ESRD), despite maximum tolerated treatment with renin-angiotensin system (RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).","primaryOutcome":{"measure":"Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months Compared to Baseline","timeFrame":"9 months","effectByArm":[{"arm":"Nefecon","deltaMin":0.69,"sd":null},{"arm":"Placebo Oral Capsule","deltaMin":0.95,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":142,"countries":["United States","Argentina","Australia","Belarus","Belgium","Canada","Czechia","Finland","France","Germany","Greece","Italy","Poland","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["28363480","39724565","37591292","36685528","36270561"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":182},"commonTop":["Nasopharyngitis","Edema peripheral","Headache","Muscle spasms","Hypertension"]}}